Albioma SA (ABIO.PA) Stock Fundamental Analysis

EPA:ABIO • FR0000060402

47.14 EUR
+0.04 (+0.08%)
Last: Sep 13, 2022, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Overall ABIO gets a fundamental rating of 2 out of 10. We evaluated ABIO against 20 industry peers in the Independent Power and Renewable Electricity Producers industry. Both the profitability and financial health of ABIO have multiple concerns. ABIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ABIO was profitable.
ABIO.PA Yearly Net Income VS EBIT VS OCF VS FCFABIO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 50M 100M 150M

1.2 Ratios

Industry RankSector Rank
ROA 2.71%
ROE 9.81%
ROIC 5.3%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABIO.PA Yearly ROA, ROE, ROICABIO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2 4 6 8 10

1.3 Margins

Industry RankSector Rank
OM 19.98%
PM (TTM) 8.98%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABIO.PA Yearly Profit, Operating, Gross MarginsABIO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ABIO is creating some value.
  • ABIO has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ABIO is higher compared to a year ago.
ABIO.PA Yearly Shares OutstandingABIO.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
ABIO.PA Yearly Total Debt VS Total AssetsABIO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 500M 1B 1.5B

2.2 Solvency

  • ABIO has an Altman-Z score of 1.46. This is a bad value and indicates that ABIO is not financially healthy and even has some risk of bankruptcy.
  • A Debt/Equity ratio of 1.68 is on the high side and indicates that ABIO has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1.68
Debt/FCF N/A
Altman-Z 1.46
ROIC/WACC1.11
WACC4.79%
ABIO.PA Yearly LT Debt VS Equity VS FCFABIO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 200M 400M 600M 800M

2.3 Liquidity

  • ABIO has a Current Ratio of 1.05. This is a normal value and indicates that ABIO is financially healthy and should not expect problems in meeting its short term obligations.
  • ABIO has a Quick Ratio of 1.05. This is a bad value and indicates that ABIO is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.75
ABIO.PA Yearly Current Assets VS Current LiabilitesABIO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.36% over the past year.
  • The Earnings Per Share has been growing by 10.59% on average over the past years. This is quite good.
  • ABIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.04%.
  • Measured over the past years, ABIO shows a quite strong growth in Revenue. The Revenue has been growing by 9.28% on average per year.
EPS 1Y (TTM)4.36%
EPS 3Y8.34%
EPS 5Y10.59%
EPS Q2Q%-11.09%
Revenue 1Y (TTM)21.04%
Revenue growth 3Y10.21%
Revenue growth 5Y9.28%
Sales Q2Q%22.65%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.39% on average over the next years.
  • Based on estimates for the next years, ABIO will show a small growth in Revenue. The Revenue will grow by 6.22% on average per year.
EPS Next Y4%
EPS Next 2Y10.38%
EPS Next 3Y7.07%
EPS Next 5Y7.39%
Revenue Next Year8.28%
Revenue Next 2Y6.4%
Revenue Next 3Y6.91%
Revenue Next 5Y6.22%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ABIO.PA Yearly Revenue VS EstimatesABIO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
ABIO.PA Yearly EPS VS EstimatesABIO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 26.94, which means the current valuation is very expensive for ABIO.
  • When comparing the Price/Earnings ratio of ABIO to the average of the S&P500 Index (27.10), we can say ABIO is valued inline with the index average.
  • A Price/Forward Earnings ratio of 21.36 indicates a rather expensive valuation of ABIO.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. ABIO is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 26.94
Fwd PE 21.36
ABIO.PA Price Earnings VS Forward Price EarningsABIO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.89
ABIO.PA Per share dataABIO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ABIO does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)6.74
PEG (5Y)2.54
EPS Next 2Y10.38%
EPS Next 3Y7.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • ABIO has a Yearly Dividend Yield of 1.78%. Purely for dividend investing, there may be better candidates out there.
  • ABIO's Dividend Yield is comparable with the S&P500 average which is at 1.83.
Industry RankSector Rank
Dividend Yield 1.78%

5.2 History

  • On average, the dividend of ABIO grows each year by 8.92%, which is quite nice.
Dividend Growth(5Y)8.92%
Div Incr YearsN/A
Div Non Decr YearsN/A
ABIO.PA Yearly Dividends per shareABIO.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 0.2 0.4 0.6 0.8

5.3 Sustainability

  • The dividend of ABIO is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DPN/A
EPS Next 2Y10.38%
EPS Next 3Y7.07%
ABIO.PA Yearly Income VS Free CF VS DividendABIO.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

More info and screens

Find the best dividend stocksShow peers with best dividend

Albioma SA

EPA:ABIO (9/13/2022, 7:00:00 PM)

47.14

+0.04 (+0.08%)

Chartmill FA Rating
GICS SectorUtilities
GICS IndustryGroupUtilities
GICS IndustryIndependent Power and Renewable Electricity Producers
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.52B
Revenue(TTM)633.91M
Net Income(TTM)56.94M
Analysts80
Price Target52.53 (11.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.78%
Yearly Dividend0.84
Dividend Growth(5Y)8.92%
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 26.94
Fwd PE 21.36
P/S 2.4
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB N/A
EV/EBITDA 11.89
EPS(TTM)1.75
EY3.71%
EPS(NY)2.21
Fwd EY4.68%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS19.64
BVpS17.99
TBVpSN/A
PEG (NY)6.74
PEG (5Y)2.54
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 2.71%
ROE 9.81%
ROCE N/A
ROIC 5.3%
ROICexc N/A
ROICexgc 5.8%
OM 19.98%
PM (TTM) 8.98%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 1.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 0.75
Altman-Z 1.46
F-Score6
WACC4.79%
ROIC/WACC1.11
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.36%
EPS 3Y8.34%
EPS 5Y10.59%
EPS Q2Q%-11.09%
EPS Next Y4%
EPS Next 2Y10.38%
EPS Next 3Y7.07%
EPS Next 5Y7.39%
Revenue 1Y (TTM)21.04%
Revenue growth 3Y10.21%
Revenue growth 5Y9.28%
Sales Q2Q%22.65%
Revenue Next Year8.28%
Revenue Next 2Y6.4%
Revenue Next 3Y6.91%
Revenue Next 5Y6.22%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Albioma SA / ABIO.PA FAQ

What is the fundamental rating for ABIO stock?

ChartMill assigns a fundamental rating of 5 / 10 to ABIO.PA.


What is the valuation status for ABIO stock?

ChartMill assigns a valuation rating of 3 / 10 to Albioma SA (ABIO.PA). This can be considered as Overvalued.


Can you provide the profitability details for Albioma SA?

Albioma SA (ABIO.PA) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for ABIO stock?

The Price/Earnings (PE) ratio for Albioma SA (ABIO.PA) is 26.94 and the Price/Book (PB) ratio is 2.62.


How financially healthy is Albioma SA?

The financial health rating of Albioma SA (ABIO.PA) is 4 / 10.